Dr Li Jia

MB, PhD
Senior Lecturer
Group Leader
Research Focus

I am interested in studying the effects of the inflammatory microenvironment on disease progression and resistance to treatment in haematological malignancies with emphasis on survival and mechanisms of treatment resistance in chronic lymphocytic leukaemia and B cell lymphoma.

Key Publications

CD126 and targeted therapy with Tocilizumab in Chronic Lymphocytic Leukemia. Clin Cancer Res (2016) 15;22(10):2462-9. PMID: 26712690

Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. Oncotarget (2015) 29;6(29):27816-31. PMID: 26315113

Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2. Oncotarget (2014) 5(22):11653-68. PMID: 25362242

Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood (2014) 123(11):1709-19. PMID: 24464016

Major Funding
  • 2015-2016- Kay Kendall Leukaemia Fund, Identification of HMGB12 as a novel therapeutic target for the treatment of chronic lymphocytic leukaemia, £136,831
  • 2016-2019: National Natural Science Foundation, China
Other Activities
  • Editorial Board: Chinese Journal of Clinical Oncology
  • Honorary Professor in Tianjin Medical University Cancer Institute and Hospital, China
Research

For over 20 years, my main research work focused on overcoming the resistance of leukaemia and lymphoma cells to chemo- or immuno-therapy, and the roles of mitochondria and BCL-2 family proteins in apoptotic cell death.

Our studies now focus on the impact of the inflammatory microenvironment on survival and treatment resistance mechanisms of chronic lymphocytic leukaemia (CLL) and B cell lymphoma.

Current research focuses are:

  • The roles of inflammatory microenvironment on CLL cell survival and resistance to novel anti-cancer drugs;
  • The impact of soluble inflammatory factors and their receptors on prognosis and clinical outcomes for patients with CLL;
  • Soluble inflammatory factor-mediated intracellular signalling network in malignant B-cells.
Other Activities
  • Editorial Board: Chinese Journal of Clinical Oncology
  • Honorary Professor in Tianjin Medical University Cancer Institute and Hospital, China
Major Funding
  • 2015-2016- Kay Kendall Leukaemia Fund, Identification of HMGB12 as a novel therapeutic target for the treatment of chronic lymphocytic leukaemia, £136,831
  • 2016-2019: National Natural Science Foundation, China
Recent Publications

Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia. Wang H-Q, Jia L, Li Y-T et al. J Cell Physiol (2019) 234(2) 13994-14006
https://www.ncbi.nlm.nih.gov/pubmed/30623437

Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma. Zhang T, Guan X-W, Gribben JG et al. Cell Death Dis (2019) 10(2) 330
https://www.ncbi.nlm.nih.gov/pubmed/30988279

Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy. Wang P-G, Li Y-T, Pan Y et al. J Neurooncol (2019) 141(2) 71-81
https://www.ncbi.nlm.nih.gov/pubmed/30446901

HIF-2-dependent expression of stem cell factor promotes metastasis in hepatocellular carcinoma. Wang X, Dong J, Jia L et al. Cancer Lett (2017) 393(2) 113-124
https://www.ncbi.nlm.nih.gov/pubmed/28153790

STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia Liu F-T, Jia L, Wang P et al. Oncotarget (2016) (1)

CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia. Liu F-T, Jia L, Wang P et al. Clin Cancer Res (2016) 22(2) 2462-2469
https://www.ncbi.nlm.nih.gov/pubmed/26712690

Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes. Wang X, Ren H, Zhao T et al. Oncotarget (2016) 7(2) 13717-13729
https://www.ncbi.nlm.nih.gov/pubmed/26872370

Overexpression of HMGB1 Receptor RAGE Is Associated with Worse Clinical Outcome in Patients with Chronic Lymphocytic Leukemia Norster F, Clear AJ, Matthews J et al. BLOOD (2015) 126(11)
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000368019002054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a

Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. Zhao T, Ren H, Wang X et al. Oncotarget (2015) 6(2) 27816-27831
https://www.ncbi.nlm.nih.gov/pubmed/26315113

Dynamin-related protein Drp1 is required for Bax translocation to mitochondria in response to irradiation-induced apoptosis. Wang P, Wang P, Liu B et al. Oncotarget (2015) 6(2) 22598-22612
https://www.ncbi.nlm.nih.gov/pubmed/26093086

For additional publications, please click here
Team

PhD Students
Ms Arantxa Romero Toledo

Biography

Education and Qualifications

  • 1994-1997: PhD in Cell Biology of Haematology. Department of Haematology, St. Bartholomew’s and The Royal London School of Medicine and Dentistry.
  • 1984-1985: Diploma in Advanced Biochemistry. NanKai University, Tianjin, China.
  • 1978-1983: Medical Bachelor (MB). China Medical University, Shenyang, China.

Career progression

  • Since Sept. 2008: Senior Lecturer. Centre for Haematological Oncology, Barts Cancer Institute, Queen Mary University of London.
  • Oct 2004-Aug 2008: Senior Lecturer. Centre for Haematology, Institute of Cell and Molecular Science.
    July 2000: Non-Clinical Lecturer and leader of the apoptosis laboratory. Centre for Haematology, Institute of Cell and Molecular Science.
  • 1997-1999: Post-doctoral Research Fellow. Department of Haematology, St. Bartholomew’s and The Royal London School of Medicine and Dentistry. Supported by Leukaemia Research Fund.
  • 1994-1996: Research Assistant and PhD student. Department of Haematology, St. Bartholomew’s and The Royal London School of Medicine and Dentistry.
  • 1989-1993: Associate Researcher Department of Biochemistry and Molecular Biology, Institute of Haematology and Blood Disease Hospital, Chinese Academy of Medical Sciences. P.R. China.
  • 1983-1989: Research Assistant. Department of Biochemistry and Molecular Biology, Institute of Haematology and Blood Disease Hospital, Chinese Academy of Medical Sciences.